Third Generation EGFR TKIs for Acquired Resistance episode artwork

EPISODE · Feb 17, 2016 · 3 MIN

Third Generation EGFR TKIs for Acquired Resistance

from GRACEcast · host cancerGRACE Meetings

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Episode metadata supplied by the publisher feed · Published Feb 17, 2016

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

PodParley-generated summary based on available episode metadata and transcript content.

NOW PLAYING

Third Generation EGFR TKIs for Acquired Resistance

0:00 3:07

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Protect Your Peace

Jul 1, 2026 ·43m

Good for Good Sake

Jun 28, 2026 ·8m

1 | The Power of the Blood

Jun 25, 2026 ·61m

10 | Reporting for Duty

Jun 24, 2026 ·51m

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 3 minutes long.

When was this GRACEcast episode published?

This episode was published on February 17, 2016.

What is this episode about?

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Can I download this GRACEcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!